| Primary information |
|---|
| sequence ID | Seq_4199 |
| Peptide sequence | KHNLGHGHKHERDQGHGHQ |
| CancerPDF_ID | CancerPDF_ID96, CancerPDF_ID1093, CancerPDF_ID3234, CancerPDF_ID8583, CancerPDF_ID8643, CancerPDF_ID9838, CancerPDF_ID12751, |
| PMID | 16896061,16395409,21136997,23667664,24416269,21533267,27058005 |
| Protein Name | HMW Kininogen,HMW Kininogen,Kininogen-1,Kininogen HMW,"Kininogen L,high MW",Kininogen-1,Kininogen-1 |
| UniprotKB Entry Name | KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN |
| Fluid | Serum,Serum,Plasma,Serum,Plasma,Serum,Serum |
| M/Z | 2209.08,2209.08,2208.0546,2208.05,2209.06,737.02,2209.11 |
| Charge | 1,1,1,1,NA,3,NA |
| Mass (in Da) | 2209.05,NA,NA,2210.34,NA,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | MALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF |
| Peptide Identification technique | Q/TOF MS/MS,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,MS/MS,LC/MS/MS,LC-MS/MS |
| Quantification Technique | NA,NA,LC-ESI-MS,NA,Affinity Chromatography,Multiple Reaction Monitoring,NA |
| Labelled/Label Free | Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | NA,less than 1 “5,NA,NA,NA,1.49,NA |
| CancerPDF_ID | CancerPDF_ID96, CancerPDF_ID1093, CancerPDF_ID3234, CancerPDF_ID8583, CancerPDF_ID8643, CancerPDF_ID9838, CancerPDF_ID12751, |
| p-Value | 1.00E-05,1.37E-04,NA,NA,less than 0.05,NA,"less than 0.001,0.207,less than 0.05" |
| Software | MASCOT,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT,MASCOT and Markerview software version 1.2,MASCOT,Proteome Discoverer |
| Length | 19,19,19,19,19,19,19 |
| Cancer Type | Metastatic thyroid carcinomas,"Advanced Prostate, Breast and Bladder cancer",Normal,"Breast cancer, Lung cancer, Rectal cancer",Cervical cancer,Lung adenocarcinoma,Breast cancer |
| Database | NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,NA,NA,Swissprot Database (57.4),SwissProt Database |
| Modification | NA,NA,NA,NA,NA,NA,NA |
| Number of Patients | 40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",67 patients and 4 healthy,62 lung adenocarcinoma and 30 healthy control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT)." |
| Regulation | NA,"Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.72, 2.07 and 1.56 in prostate, bladder and breast cancer respectively",NA,NA,Downregulated in cancer vs normal,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Upregulated with the fold change of 0.31 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.29, Upregulated in BC vs healthy with 1.499 fold change" |
| Validation | Independent validation,Independent validation,Leave One out Cross validation,NA,NA,MRM-based validation of 19 candidates,NA |
| Sensitivity | 95% on independent dataset,97.5% on independent validation dataset,NA,NA,NA,NA,NA |
| Specificity | 95% on independent dataset,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,97.5 % on validation dataset,NA,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |